Last edition
News about "Balyasny Asset Management"
Ambros Therapeutics Launches with USD 125 Million Series A to Advance CRPS Therapy
Ambros Therapeutics has launched with a USD 125 million Series A financing to advance neridronate for Complex Regional Pain Syndrome Type 1, supported by multiple FDA designations and an oversubscribed round led by RA Capital Management and Patient Square Capital, with a pivotal phase III trial planned for early 2026.
Balyasny Asset Management | 19/12/2025 | By News Bureau | 390
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy